The incentives in the permanent “doc-fix” legislation, which now has overwhelming bipartisan support from both houses of Congress and the president, will not, by themselves, drive physicians toward value-based compensation schemes.
With the GOP holding 24 of 34 Senate seats up for grabs in the next election, the Republican-controlled Senate wisely snubbed the House-backed budget resolution last week.
Federalism is supposed to protect political accountability.
Over the past two years, conventional wisdom presumed without offering much in the way of evidence that the lingering recession and the rise of high-deductible and narrow network plans explained the slowdown in healthcare spending, now in its fifth year.
Financial markets have sent another signal that the coming era of precision or personalized medicine could wind up making cancer care unaffordable for millions of people.
A victory for the petitioners in King v. Burwell will not return the healthcare insurance marketplace to the pre-Affordable Care Act status quo.
Healthcare spending grew faster than the rest of the economy last year despite the ongoing reduction in hospital use and an industrywide campaign to hold down costs. How can that be?
Forget the smiley face the administration will put on the final numbers from the Affordable Care Act open-enrollment season that just ended. Sign-ups are lagging far behind original projections. And with the political and legal landscape littered with landmines, it's not going to get any easier.
Despite the extraordinary gains in public health brought about by vaccinations, there has never been a shortage of people who balk at the scientifically proven method for preventing infectious disease.
The dictionary defines vaporware as a product that has been widely advertised but has not and may never become available. Last week's twin announcements on the imminent move to widespread value-based reimbursement in healthcare bring the concept to mind.
Nearly two decades ago, Harvard Business School professor Clayton Christensen coined the phrase “disruptive innovation” to describe new technologies that transform industries by bringing simplicity and affordability to products and processes that are complicated and high cost.
The Food and Drug Administration's proposal to regulate the accuracy of laboratory-developed tests has drawn heated opposition from the laboratory testing industry, hospitals and most medical specialty societies. Only oncologists favor tighter oversight.